CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 195 filers reported holding CHEMOCENTRYX INC in Q4 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $43,654,000 | +97.6% | 845,023 | -5.2% | 0.02% | +100.0% |
| Q2 2022 | $22,096,000 | +62.6% | 891,678 | +59.5% | 0.01% | +125.0% |
| Q1 2022 | $13,587,000 | -3.2% | 558,876 | +45.0% | 0.00% | 0.0% |
| Q4 2021 | $14,033,000 | +296.3% | 385,423 | +86.1% | 0.00% | +300.0% |
| Q3 2021 | $3,541,000 | +20.6% | 207,098 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $2,936,000 | -87.9% | 219,227 | -53.6% | 0.00% | -87.5% |
| Q1 2021 | $24,222,000 | +1277.0% | 472,715 | +116.5% | 0.01% | +700.0% |
| Q4 2020 | $1,759,000 | -56.2% | 218,313 | -56.1% | 0.00% | -50.0% |
| Q3 2020 | $4,012,000 | +14.6% | 497,809 | +14.6% | 0.00% | +100.0% |
| Q2 2020 | $3,501,000 | -80.6% | 434,381 | -3.3% | 0.00% | -88.9% |
| Q1 2020 | $18,056,000 | +16.8% | 449,387 | +15.0% | 0.01% | +50.0% |
| Q4 2019 | $15,459,000 | +808.3% | 390,853 | +55.7% | 0.01% | +500.0% |
| Q3 2019 | $1,702,000 | -54.6% | 250,960 | -37.8% | 0.00% | 0.0% |
| Q2 2019 | $3,750,000 | – | 403,279 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |